Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30
U.S. Biotech Industry Analysis
UpdatedMay 01, 2024
DataAggregated Company Financials
Companies577
- 7D-1.5%
- 3M-3.6%
- 1Y0.1%
- YTDn/a
Over the last 7 days, the Biotech industry has remained flat, although notably Biogen gained 11%. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 23% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 01 May 2024 | US$1.1t | US$164.6b | -US$27,373,262,846.23 | 22.9x | -39.5x | 6.6x |
| Fri, 29 Mar 2024 | US$1.2t | US$164.4b | -US$23,753,804,933.92 | 21.4x | -49.6x | 7.2x |
| Sun, 25 Feb 2024 | US$1.2t | US$166.6b | -US$21,694,949,476.21 | 10.8x | -54.3x | 7.1x |
| Tue, 23 Jan 2024 | US$1.4t | US$204.8b | -US$22,505,965,323.00 | 18.5x | -63.5x | 7x |
| Thu, 21 Dec 2023 | US$1.4t | US$204.8b | -US$22,158,313,482.00 | 18.8x | -61.2x | 6.6x |
| Sat, 18 Nov 2023 | US$1.2t | US$204.7b | -US$22,079,363,558.00 | 18.1x | -54.7x | 5.9x |
| Mon, 16 Oct 2023 | US$1.3t | US$207.3b | -US$13,079,327,258.00 | 16.6x | -96.8x | 6.1x |
| Wed, 13 Sep 2023 | US$1.3t | US$207.5b | -US$12,640,460,182.00 | 17.5x | -101.7x | 6.2x |
| Fri, 11 Aug 2023 | US$1.3t | US$207.7b | -US$12,610,114,686.00 | 17.6x | -101.5x | 6.2x |
| Sun, 09 Jul 2023 | US$1.1t | US$186.3b | -US$16,022,507,026.00 | 12.9x | -69.1x | 5.9x |
| Tue, 06 Jun 2023 | US$1.1t | US$185.9b | -US$16,008,078,695.00 | 11.3x | -71.1x | 6.1x |
| Thu, 04 May 2023 | US$1.2t | US$197.6b | -US$7,506,497,270.00 | 14.1x | -154.8x | 5.9x |
| Sat, 01 Apr 2023 | US$1.2t | US$217.0b | -US$6,161,813,969.00 | 14.3x | -188.1x | 5.3x |
| Mon, 27 Feb 2023 | US$1.1t | US$199.7b | -US$4,454,800,065.00 | 14.2x | -251.9x | 5.6x |
| Wed, 25 Jan 2023 | US$1.2t | US$203.8b | US$1.8b | 14.7x | 662.2x | 5.7x |
| Fri, 23 Dec 2022 | US$1.2t | US$203.2b | US$1.6b | 14.6x | 721.2x | 5.8x |
| Sun, 20 Nov 2022 | US$1.1t | US$202.3b | US$1.2b | 14.7x | 931.7x | 5.6x |
| Tue, 18 Oct 2022 | US$1.0t | US$206.0b | US$5.4b | 15.6x | 194.3x | 5.1x |
| Thu, 15 Sep 2022 | US$1.1t | US$206.6b | US$5.7b | 15.4x | 186.4x | 5.2x |
| Sat, 13 Aug 2022 | US$1.1t | US$206.8b | US$7.3b | 15.9x | 154x | 5.4x |
| Mon, 11 Jul 2022 | US$1.1t | US$211.5b | US$10.8b | 17.4x | 102.3x | 5.2x |
| Wed, 08 Jun 2022 | US$1.0t | US$212.7b | US$11.3b | 16.6x | 90.2x | 4.8x |
| Fri, 06 May 2022 | US$1.0t | US$205.8b | US$10.3b | 17.1x | 99x | 5x |
| Sun, 03 Apr 2022 | US$1.3t | US$227.1b | US$14.5b | 18.7x | 89.7x | 5.7x |
| Tue, 01 Mar 2022 | US$1.2t | US$222.8b | US$10.9b | 19.8x | 113.4x | 5.5x |
| Thu, 27 Jan 2022 | US$1.2t | US$212.0b | US$2.4b | 22.6x | 504x | 5.7x |
| Sat, 25 Dec 2021 | US$1.4t | US$212.0b | US$2.8b | 26.1x | 519.7x | 6.8x |
| Mon, 22 Nov 2021 | US$1.5t | US$212.1b | US$3.3b | 27.1x | 442.6x | 6.9x |
| Wed, 20 Oct 2021 | US$1.5t | US$196.4b | -US$2,595,904,896.00 | 24.1x | -568.7x | 7.5x |
| Fri, 17 Sep 2021 | US$1.6t | US$196.3b | -US$2,214,200,348.00 | 25.5x | -723x | 8.2x |
| Sun, 15 Aug 2021 | US$1.6t | US$197.0b | -US$1,662,914,785.58 | 22.7x | -936x | 7.9x |
| Thu, 10 Jun 2021 | US$1.4t | US$174.8b | -US$11,505,542,875.55 | 22.2x | -120.4x | 7.9x |
Price to Earnings Ratio
-127.4x
Current Industry PE
- Investors are relatively neutral on the American Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.2x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Meanwhile revenues have remained mostly flat.
- This means that although sales have remained flat, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Comparison
How does U.S. Biotech compare with similar industries?
| US Market | -0.72% | |
| Healthcare | -0.55% | |
| Biotech | -1.47% | |
| Biotech | -1.47% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BIIB Biogen | US$214.82 | 11.2% +US$3.2b | -30.5% | PE26.8x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| IBRX ImmunityBio | US$7.99 | 45.5% +US$1.7b | 159.4% | PS8696.6x | |
| VKTX Viking Therapeutics | US$79.58 | 22.6% +US$1.6b | 279.0% | PB9.4x | |
| BGNE BeiGene | US$153.94 | 10.8% +US$1.6b | -41.6% | PS6.5x |